<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02009696</url>
  </required_header>
  <id_info>
    <org_study_id>G120226 (Phase B)</org_study_id>
    <nct_id>NCT02009696</nct_id>
  </id_info>
  <brief_title>ProMRI Study of the Entovis Pacemaker System (Phase B)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the ProMRI Study (Phase B) is to demonstrate the clinical safety of the
      ProMRI Pacemaker System when used under specific MRI conditions without scan exclusion zone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MRI and Pacing System Related Serious Adverse Device Effect (SADE) Free Rate</measure>
    <time_frame>1 Month Post-MRI</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Free of Atrial Pacing Threshold Rise</measure>
    <time_frame>Between Pre-MRI and 1 Month Post-MRI</time_frame>
    <description>Evaluate the percentage of atrial pacing leads with a pacing threshold increaess between the Pre-MRI and one-month post-MRI follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Free of Ventricular Pacing Threshold Rise</measure>
    <time_frame>Between Pre-MRI and 1 Month Post-MRI</time_frame>
    <description>Evaluate the percentage of ventricular pacing leads with a pacing threshold increase between the Pre-MRI and one-month post-MRI follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Free of P-wave Sensing Attenuation</measure>
    <time_frame>Between Pre-MRI and 1 Month Post-MRI</time_frame>
    <description>Evaluate the percentage of subjects who experience P-wave attenuation between the pre-MRI and one-month post-MRI follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Free of R-wave Sensing Attenuation</measure>
    <time_frame>Between Pre-MRI and 1 Month Post-MRI</time_frame>
    <description>Evaluate the percentage of subjects who experience R-wave attenuation between the pre-MRI and one-month post-MRI follow-up.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">221</enrollment>
  <condition>Magnetic Resonance Imaging (MRI); Cardiac Pacing</condition>
  <arm_group>
    <arm_group_label>Pacemaker Therapy</arm_group_label>
    <description>Patients with a ProMRI Pacemaker System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Patients with a ProMRI Pacemaker System</intervention_name>
    <description>Bradycardia Slow Heart Beat</description>
    <arm_group_label>Pacemaker Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic Resonance Imaging (MRI) scan</intervention_name>
    <description>MRI scan of heart/chest or thoracic spine.</description>
    <arm_group_label>Pacemaker Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients selected for participation should be from the investigators' general patient
        population according to the inclusion and exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The following initial inclusion criteria must be met for a subject to be enrolled and
        considered for the MRI-procedure:

          -  Age greater than 18 years

          -  Able and willing to complete MRI testing

          -  Able to provide written informed consent

          -  Available for follow-up visit at the study site

          -  Implanted with a pacemaker system consisting only of an Entovis pacemaker (DR-T, SR-T)
             and one or two Setrox S 53 or Setrox S 60 pacemaker lead(s). (No leads other than
             Setrox S (53 or 60 cm) leads may be implanted. This includes lead extensions or
             abandoned leads in the subject.)

          -  Pacemaker implanted pectorally

          -  All pacemaker system components implanted, repositioned, or exchanged at least 5 weeks
             prior to enrollment

          -  Underling rhythm identifiable during sensing test

          -  All pacing thresholds are measureable and are less than or equal to 2.0 V @0.4 ms

          -  Absence of phrenic nerve stimulation at 4.8V @ 1.0 ms

          -  Pacing impedance is between 200 and 1500 ohm

          -  Able and willing to use the Cardio Messenger

        At the pre-MRI procedure, the following procedure-related criteria must be met for the
        subject to undergo the MRI scan:

          -  Absence of phrenic nerve stimulation at 4.8V @ 1.0 ms

             •|pacing threshold at Pre-MRI follow-up - pacing threshold at baseline| ≤ 0.5 V

          -  All pacing thresholds are measureable and are ≤ 2.0 V @ 0.4 ms

          -  The pacemaker system has been implanted for at least 6 weeks.

          -  Subject did not have a pacemaker or lead explant, exchange or reposition in the
             previous 6 weeks.

          -  All lead impedances are between 200 and 1500 ohm.

          -  Battery status is at least 30% of capacity

        Exclusion Criteria:

          -  Enrolled in any other clinical study

          -  For pacemaker systems that include an atrial lead, subjects with either

               -  Persistent atrial arrhythmia (lasting longer than 7 days or requiring
                  cardioversion)

               -  Permanent atrial arrhythmia

          -  Life expectancy of less than three months

          -  Pregnancy

          -  Cardiac surgery expected in the next three months

        Implanted with other medical devices that may interact with MRI, such as:

          -  abandoned pacemaker/ICD leads

          -  lead extensions

          -  mechanical valves

          -  other active medical devices

          -  non-MRI compatible devices

          -  other metallic artifacts/components in body that may interact with MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19702-5438</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <zip>46383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10463</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <zip>97301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newtown</city>
        <state>Pennsylvania</state>
        <zip>18940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mechanicsville</city>
        <state>Virginia</state>
        <zip>23116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bailey WM, Mazur A, McCotter C, Woodard PK, Rosenthal L, Johnson W, Mela T; ProMRI Study Investigators. Clinical safety of the ProMRI pacemaker system in patients subjected to thoracic spine and cardiac 1.5-T magnetic resonance imaging scanning conditions. Heart Rhythm. 2016 Feb;13(2):464-71. doi: 10.1016/j.hrthm.2015.09.021. Epub 2015 Sep 25.</citation>
    <PMID>26409098</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2013</study_first_posted>
  <results_first_submitted>June 17, 2015</results_first_submitted>
  <results_first_submitted_qc>June 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 10, 2015</results_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pacemaker Therapy</title>
          <description>Patients with a ProMRI Pacemaker System
Patients with a ProMRI Pacemaker System: Bradycardia Slow Heart Beat
Magnetic Resonance Imaging (MRI) scan: MRI scan of heart/chest or thoracic spine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pacemaker Therapy</title>
          <description>Patients with a ProMRI Pacemaker System
Patients with a ProMRI Pacemaker System: Bradycardia Slow Heart Beat
Magnetic Resonance Imaging (MRI) scan: MRI scan of heart/chest or thoracic spine.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="221"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.4" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MRI and Pacing System Related Serious Adverse Device Effect (SADE) Free Rate</title>
        <time_frame>1 Month Post-MRI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pacemaker Therapy</title>
            <description>Patients with a ProMRI Pacemaker System
Patients with a ProMRI Pacemaker System: Bradycardia Slow Heart Beat
Magnetic Resonance Imaging (MRI) scan: MRI scan of heart/chest or thoracic spine.</description>
          </group>
        </group_list>
        <measure>
          <title>MRI and Pacing System Related Serious Adverse Device Effect (SADE) Free Rate</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="97.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Free of Atrial Pacing Threshold Rise</title>
        <description>Evaluate the percentage of atrial pacing leads with a pacing threshold increaess between the Pre-MRI and one-month post-MRI follow-up.</description>
        <time_frame>Between Pre-MRI and 1 Month Post-MRI</time_frame>
        <population>Number of participants with an atrial lead and same atrial threshold polarity (either uni- or bi-polar) at pre-MRI and one-month post-MRI.</population>
        <group_list>
          <group group_id="O1">
            <title>Pacemaker Therapy</title>
            <description>Patients with a ProMRI Pacemaker System
Patients with a ProMRI Pacemaker System: Bradycardia Slow Heart Beat
Magnetic Resonance Imaging (MRI) scan: MRI scan of heart/chest or thoracic spine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Free of Atrial Pacing Threshold Rise</title>
          <description>Evaluate the percentage of atrial pacing leads with a pacing threshold increaess between the Pre-MRI and one-month post-MRI follow-up.</description>
          <population>Number of participants with an atrial lead and same atrial threshold polarity (either uni- or bi-polar) at pre-MRI and one-month post-MRI.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Free of Ventricular Pacing Threshold Rise</title>
        <description>Evaluate the percentage of ventricular pacing leads with a pacing threshold increase between the Pre-MRI and one-month post-MRI follow-up.</description>
        <time_frame>Between Pre-MRI and 1 Month Post-MRI</time_frame>
        <population>Number of participants with a ventricular lead and same ventricular threshold polarity (either uni- or bi-polar) at pre-MRI and one-month post-MRI.</population>
        <group_list>
          <group group_id="O1">
            <title>Pacemaker Therapy</title>
            <description>Patients with a ProMRI Pacemaker System
Patients with a ProMRI Pacemaker System: Bradycardia Slow Heart Beat
Magnetic Resonance Imaging (MRI) scan: MRI scan of heart/chest or thoracic spine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Free of Ventricular Pacing Threshold Rise</title>
          <description>Evaluate the percentage of ventricular pacing leads with a pacing threshold increase between the Pre-MRI and one-month post-MRI follow-up.</description>
          <population>Number of participants with a ventricular lead and same ventricular threshold polarity (either uni- or bi-polar) at pre-MRI and one-month post-MRI.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Free of P-wave Sensing Attenuation</title>
        <description>Evaluate the percentage of subjects who experience P-wave attenuation between the pre-MRI and one-month post-MRI follow-up.</description>
        <time_frame>Between Pre-MRI and 1 Month Post-MRI</time_frame>
        <population>Number of participants with an atrial lead and same sensing polarity (either uni- or bi-polar) at pre-MRI and one-month post-MRI.</population>
        <group_list>
          <group group_id="O1">
            <title>Pacemaker Therapy</title>
            <description>Patients with a ProMRI Pacemaker System
Patients with a ProMRI Pacemaker System: Bradycardia Slow Heart Beat
Magnetic Resonance Imaging (MRI) scan: MRI scan of heart/chest or thoracic spine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Free of P-wave Sensing Attenuation</title>
          <description>Evaluate the percentage of subjects who experience P-wave attenuation between the pre-MRI and one-month post-MRI follow-up.</description>
          <population>Number of participants with an atrial lead and same sensing polarity (either uni- or bi-polar) at pre-MRI and one-month post-MRI.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="94.9" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Free of R-wave Sensing Attenuation</title>
        <description>Evaluate the percentage of subjects who experience R-wave attenuation between the pre-MRI and one-month post-MRI follow-up.</description>
        <time_frame>Between Pre-MRI and 1 Month Post-MRI</time_frame>
        <population>Number of participants with a ventricular lead and same ventricular sensing polarity (either uni- or bi-polar) at pre-MRI and one-month post-MRI.</population>
        <group_list>
          <group group_id="O1">
            <title>Pacemaker Therapy</title>
            <description>Patients with a ProMRI Pacemaker System
Patients with a ProMRI Pacemaker System: Bradycardia Slow Heart Beat
Magnetic Resonance Imaging (MRI) scan: MRI scan of heart/chest or thoracic spine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Free of R-wave Sensing Attenuation</title>
          <description>Evaluate the percentage of subjects who experience R-wave attenuation between the pre-MRI and one-month post-MRI follow-up.</description>
          <population>Number of participants with a ventricular lead and same ventricular sensing polarity (either uni- or bi-polar) at pre-MRI and one-month post-MRI.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pacemaker Therapy</title>
          <description>Patients with a ProMRI Pacemaker System
Patients with a ProMRI Pacemaker System: Bradycardia Slow Heart Beat
Magnetic Resonance Imaging (MRI) scan: MRI scan of heart/chest or thoracic spine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Syncope/Pre-Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Worsening Chronic Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Medication Related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Vascular Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>MRI Incidental Finding</sub_title>
                <counts group_id="E1" events="41" subjects_affected="38" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigators agree to submit copies of any manuscript proposed for publication to Sponsor for review at least 30 days in advance of submission for publication or presentation. Sponsor may extend such review period for another 90 days to file patent applications or take other steps to protect its intellectual property interests, or to remove from the paper or presentation any language that is detrimental to Sponsor's intellectual property interests.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Studies Engineer</name_or_title>
      <organization>Biotronik, Inc.</organization>
      <phone>503-927-7230</phone>
      <email>justin.michalski@biotronik.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

